CD19 CAR T-cell therapy for B-cell acute lymphoblastic leukemia
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This early-phase trial tests a personalized cancer treatment using your own immune cells (called CAR T-cells) to target and kill leukemia cells that have a specific marker (CD19). It may be an option for adults with B-cell acute lymphoblastic leukemia (B-ALL) who haven't had this type of therapy before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with B-cell acute lymphoblastic leukemia (B-ALL) and your leukemia cells have the CD19 marker.
- You are expected to live at least 12 weeks.
- You are generally able to take care of yourself (ECOG score 0-2).
- Your kidneys, liver, and heart function are adequate (based on standard lab tests).
- You have not had a severe allergic reaction or brain/nerve side effects from a previous CAR T-cell therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a one-time CAR T-cell treatment aimed at CD19, a target found on many B-cell leukemias and lymphomas. It’s for people whose disease has come back or hasn’t responded to prior treatments, or who can’t have a stem cell transplant.
This trial tests a new treatment using your own immune cells (called CAR-T cells) that have been modified to find and kill cancer cells with a marker called CD19. It is for adults newly diagnosed with B-cell acute lymphoblastic leukemia or lymphoma who cannot handle strong chemotherapy due to health reasons.
This trial tests a new immunotherapy using your own immune cells (CAR T-cells) that are modified to find and kill cancer cells that have a protein called CD19 or CD22. It is for adults whose acute lymphoblastic leukemia (ALL) or lymphoma has come back or did not respond to previous treatments.
This trial tests whether specially designed immune cells (CAR T cells) that target CD19 can help adults whose B-cell acute lymphoblastic leukemia has not responded to standard treatments or has returned. The cells are made from your own blood and given back to you after a short chemotherapy preparation.
This trial tests a new immune therapy that uses your own cells (CAR T-cells) to find and attack cancer cells with the CD19 protein. It is for people with certain types of leukemia or lymphoma that have not responded to other treatments.
This trial tests a one-time, lab-made immune cell treatment (CD19 CAR-T) for certain B-cell blood cancers in children and young adults. It may help people whose leukemia or lymphoma is not responding to standard treatment or has come back.
Hear when a new B-Cell Acute Lymphoblastic Leukemia, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.